Prof. Dr. Vladimir Gevorgyan, University of Texas at Dallas, USA

New Heterocyclization and C–H Functionalization Methods

Session1

Session3

Prof. Dr. Dmitriy Volochnyuk, Institute of Organic Chemistry NAS of Ukraine, UA

Amino Acids Derived Diazoketones – Shelf Stable Reagents for Heterocyclizations

Prof.  Dr. Tambet Teesalu, University of Tartu, EE

Precision Targeting of Drugs and Nanoparticles with Homing Peptides

Prof. Dr. Sergey Ryabukhin, TS National University of Kyiv & Enamine, UA

MedChem-Relevant gem-Difluorocycloalkane Building Blocks and Their Impact on Physicochemical Properties

Prof. Dr. Valentín Ceña, Universidad de Castilla-La Mancha, ES

Nanomedicine for Glioblastoma Therapy

Prof. Dr. Till Opatz, Johannes Gutenberg-University Mainz, DE

Chemical Contributions to Fighting and Preventing Prevalent Diseases

Dr. Antons Sizovs, Latvian Institute of Organic Synthesis, LV

Pharmacokinetics, Biodistribution and Passive Tumor Accumulation of Non-opsonizing Nanoparticles

Session2

Dr. Sigitas Mikutis, University of Cambridge, UK

Small Molecule Targeted RNA Degraders – RNA Modifications, SARS-CoV-2 and Beyond

Prof. Dr. Igor Komarov, TS National University of Kyiv & Enamine, UA

Diarylethenes as Promising Drug Candidates for Photopharmacology

Dr. Ross McLennan, University of Dundee, Scotland, UK

Rational Design of a SMARCA2 Selective and Orally Bioavailable VHL-recruiting PROTAC

Prof. Dr. Christopher Schofield, University of Oxford, UK

Adventures with Oxygen - from basic science to new drugs

Prof. Dr. Rolf Müller, Helmholtz-Insititute for Pharmaceutical Research, DE

Approaches Towards Innovative Antibiotics from Microbes

Session4

Session7

Prof. Dr. Fredrik Björkling, University of Copenhagen, DK

Activity-enhanced Antimicrobial Peptides

Prof. Dr. Ilze Konrāde, Rīga Stradiņš University, LV

Cardiometabolic Effects of New Classes of Antidiabetic Agents: a way back to cardiomyocytes

Dr. Jürgen Brem, Janssen: Pharmaceutical Companies of Johnson & Johnson, BE

Industry Academia Collaboration in AMR R&D: Does it Take Two to Tango?

Prof. Dr. Lisa Chakrabarti, University of Nottingham, UK

Testing Repurposed Drugs for Neurodegeneration via Mitochondrial Profiling

Prof. Dr. Paul Finn, Oxford Drug Design, UK

Discovery of Potent Gram-negative Antibacterials Targeting Leucyl-tRNA Synthetase

Prof. Dr. Steen Larsen, University of Copenhagen, DK

Effects of Exercise on Energy Metabolism – Focus on Mitochondrial Adaptations

Session5

Session8

Prof. Dr. Jean-Yves Winum, University of Montpellier, FR

Multivalent Approach to Targeting Carbonic Anhydrases

Prof. Dr. Asla Pitkänen, University of Eastern Finland, FI

Systems Biology-Derived Network Treatments for Traumatic Brain Injury and Post-Traumatic Epilepsy - Lessons Learned

Prof. Dr. Alessio Nocentini, University of Florence, IT

Multi-targeted Chemotherapeutics Hitting G-quadruplex Foldings and Cancer-related Human Carbonic Anhydrases

Prof. Dr. Jens Pahnke, University of Oslo, NO

ABC Transporter Blood-brain Barrier Function in Neurodegenerative and Neuroinflammatory Diseases – From Basic Research to Treatment

Prof. Dr. Michael  Gütschow, University of Bonn, DE

Redirecting the Peptide Cleavage: Novel Cathepsin B Inhibitors with Inversely Oriented Warheads

Prof. Dr. Sven M. Stefan, University of Oslo, NO

Exploring Uncharted Pharmacological Space to Uncover Drug Targets of the Future

Dr. Pavel Arsenyan, Latvian Institute of Organic Synthesis, LV

Selenium in Drug Discovery: A Blessing and a Curse

Dr. Līga Zvejniece, Latvian Institute of Organic Synthesis, LV

Metabolomic Signature of Sigma-1 receptor Knock-out Mice

Session6

Fragment-based drug discovery

Natural compounds

Dr. Emilio Parisini, Latvian Institute of Organic Synthesis, LV

Towards the Development of Selective Modulators of Cadherin-mediated cell-cell Adhesion

Prof. Dr. Nina Hermans, University of Antwerp, BE

Bioavailability and Biotransformation of Polyphenolic Compounds:  Does the Gut Microbiome Play a Lead Role?

Dr. Daren Fearon, Diamond Light Source Ltd, UK

From Crystallographic Fragment Screen to Preclinical Candidates: Open Science Discovery of New Antivirals

Ilona Vanaga, University of Latvia, LV

Ancient Survivors - Conifer Polyprenol Studies for Modern Applications

Prof. Dr. Amedeo Caflisch, University of Zurich, CH

Structure-based Optimization of an Anticancer Compound

Dr. Inga Sīle, Latvian Institute of Organic Synthesis, LV

Medicinal Plants in Latvia: Traditional Knowledge and Future Perspectives

Prof. Dr. David Crich, University of Georgia, USA

Hydroxalogs

Dr. David Rees, Astex Pharmaceuticals, UK 

Medicines for Millions of Patients

Session9

Prof. Dr. Bengt Erik Haug, University of Bergen, NO

Synthesis of Bioactive Marine Natural Products

Prof. Dr. Pau Gorostiza, Institute for Bioengineering of Catalonia, ES

Structure-based Design of Photoswitchable Ligands Targeting Enzymes and Receptors

Prof. Dr. Edgars Sūna, Latvian Institute of Organic Synthesis, LV

Anti-cancer hit from natural product: from total synthesis to drug discovery

Prof. Dr. Marko Hyvonen, University of Cambridge, UK

Development of Orthosteric Inhibitors of RAD51:BRCA2 Interaction

Prof. Dr. Martin Hällberg, Karolinska Institute, SE

Structural Virology for Drug Design

Prof. Dr. Jieping Zhu, EPFL, CH

Catalytic Enantioselective 1,2-Rearrangement